Wells Fargo analyst Jim Birchenough downgrades Sangamo Therapeutics (NASDAQ:SGMO) from Overweight to Equal-Weight and announces $1 price target.
Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight, Announces $1 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.